MX2010005451A - Sistema para la liberacion en una celula positiva para xcr1 y usos de este. - Google Patents
Sistema para la liberacion en una celula positiva para xcr1 y usos de este.Info
- Publication number
- MX2010005451A MX2010005451A MX2010005451A MX2010005451A MX2010005451A MX 2010005451 A MX2010005451 A MX 2010005451A MX 2010005451 A MX2010005451 A MX 2010005451A MX 2010005451 A MX2010005451 A MX 2010005451A MX 2010005451 A MX2010005451 A MX 2010005451A
- Authority
- MX
- Mexico
- Prior art keywords
- delivery
- positive cell
- xcr1
- delivery system
- nucleic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a un sistema de liberación adecuado para liberar una sustancia en una célula presentadora de antígeno, profesional, positiva para XCRl, uno o más ácidos nucleicos que codifican para éste, un vector que contiene el(los) ácidos(s) nucleico(s), un medicamento que comprende el sistema de liberación o el uno o más ácido(s) nucleico(s) y un adyuvante que contiene XCL1 o un fragmento funcional activo de éste.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07022471A EP2062592A1 (en) | 2007-11-20 | 2007-11-20 | System for delivery into a XCR1 positive cell and uses thereof |
US1326307P | 2007-12-12 | 2007-12-12 | |
PCT/EP2008/009758 WO2009065561A2 (en) | 2007-11-20 | 2008-11-19 | System for delivery into a xcr1 positive cell and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010005451A true MX2010005451A (es) | 2010-08-09 |
Family
ID=39267731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010005451A MX2010005451A (es) | 2007-11-20 | 2008-11-19 | Sistema para la liberacion en una celula positiva para xcr1 y usos de este. |
Country Status (9)
Country | Link |
---|---|
US (1) | US10703817B2 (es) |
EP (2) | EP2062592A1 (es) |
JP (2) | JP2011503219A (es) |
CN (1) | CN101896191B (es) |
AU (1) | AU2008328183B2 (es) |
BR (1) | BRPI0819295A2 (es) |
CA (1) | CA2705588A1 (es) |
MX (1) | MX2010005451A (es) |
WO (1) | WO2009065561A2 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120315324A1 (en) * | 2010-02-05 | 2012-12-13 | University Of Louisville Research Foundation, Inc. | Exosomal compositions and methods for the treatment of disease |
JP5989096B2 (ja) * | 2011-09-01 | 2016-09-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗ヒトxcr1抗体 |
AU2012311238A1 (en) * | 2011-09-23 | 2014-04-17 | University Of Oslo | Vaccibodies targeted to cross-presenting dendritic cells |
WO2013070324A1 (en) | 2011-11-07 | 2013-05-16 | University Of Louisville Research Foundation, Inc. | Edible plant-derived microvesicle compositions for diagnosis and treatment of disease |
US20130245236A1 (en) * | 2012-03-15 | 2013-09-19 | Richard Kroczek | Antibodies to the chemokine receptor xcr1 |
ES2906598T3 (es) | 2014-03-17 | 2022-04-19 | Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch Inst Vertreten Durch Seinen Praeside | Un medicamento para el uso en un método para inducir o extender una respuesta inmunitaria citotóxica celular |
KR20170051462A (ko) * | 2014-08-28 | 2017-05-11 | 아카데미슈 지켄후이스 라이덴 | Cd94/nkg2a 및/또는 cd94/nkg2b 항체, 백신 조합물 |
KR101833971B1 (ko) * | 2016-02-19 | 2018-03-02 | 사회복지법인 삼성생명공익재단 | 중간엽 줄기세포 또는 xcl1을 포함하는 근육질환의 예방 또는 치료용 약학적 조성물 |
CN105777909B (zh) * | 2016-03-03 | 2020-04-03 | 中国农业科学院兰州兽医研究所 | 一种猪趋化因子介导的a型口蹄疫靶向性复合表位蛋白及疫苗 |
CN105622762B (zh) * | 2016-03-03 | 2020-04-03 | 中国农业科学院兰州兽医研究所 | 一种牛趋化因子介导的o型口蹄疫靶向性复合表位蛋白及疫苗 |
CN107056932B (zh) * | 2016-12-24 | 2021-04-09 | 深圳大学 | 一种氨基酸序列、含ova表位的融合蛋白及其制备方法和应用 |
MA48047A (fr) * | 2017-04-05 | 2020-02-12 | Modernatx Inc | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
US10815520B2 (en) | 2017-04-07 | 2020-10-27 | University Of Louisville Research Foundation, Inc. | Nanovesicles, methods, and systems for diagnosis and prognosis of cancer |
JP2021529535A (ja) * | 2018-07-02 | 2021-11-04 | ピュアテック エルワイティー, インコーポレイテッド | 生物学的薬剤の送達に使用する乳小胞 |
WO2020127277A1 (en) | 2018-12-18 | 2020-06-25 | Robert Koch-Institut | A peptide-loaded mhc-i presenting cell and an il-2 with extended half-life for amplifying a cellular cytotoxic immune response |
JP2022515473A (ja) * | 2018-12-28 | 2022-02-18 | エフ.ホフマン-ラ ロシュ アーゲー | 免疫応答が増幅された患者における治療的使用のためのペプチド-mhc-i-抗体融合タンパク質 |
CN109609505A (zh) * | 2019-01-14 | 2019-04-12 | 中国科学院成都生物研究所 | 一种体内筛选的剪切rna的锤头状核酶 |
JP2023504659A (ja) | 2019-12-03 | 2023-02-06 | ニューボーゲン,インコーポレイティド | 腫瘍細胞ワクチン |
CN113072647B (zh) * | 2021-06-04 | 2021-08-13 | 诺未科技(北京)有限公司 | 靶向人乳头瘤病毒的核酸疫苗 |
CN113072646A (zh) * | 2021-06-04 | 2021-07-06 | 北京承诺未来科技有限公司 | 靶向egfr的肿瘤核酸疫苗 |
WO2024015955A2 (en) * | 2022-07-15 | 2024-01-18 | President And Fellows Of Harvard College | Mucispirillum compositions and cancer treatment methods thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5780268A (en) * | 1995-12-06 | 1998-07-14 | Incyte Pharmaceuticals | Chemokine expressed in a mixed lymphocyte reaction |
US6395268B1 (en) * | 1996-10-24 | 2002-05-28 | Schering Corporation | Lymphotactin uses |
US6153182A (en) | 1997-12-19 | 2000-11-28 | Uab Research Foundation | Lymphotactin as an adjuvant |
US7157418B1 (en) | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
DK1098664T3 (da) * | 1998-07-22 | 2003-11-17 | Osprey Pharmaceuticals Ltd | Sammensætninger og deres anvendelser til at behandle sekundær vævsskade og andre inflammatoriske tilstande og forstyrrelser |
DE69929232T2 (de) | 1998-10-21 | 2006-08-31 | The United States Government As Represented By The Department Of Health And Human Services | Virusähnliche partikel zur induktion von autoantikörpern |
US20030124627A1 (en) * | 2001-11-29 | 2003-07-03 | Burmer Glenna C. | Diagnostic and therapeutic compositions and methods related to chemokine (C motif ) XC receptor 1 (CCXCR1), a G protein-coupled receptor (GPCR) |
KR100442963B1 (ko) | 2001-12-29 | 2004-08-04 | 주식회사 하이닉스반도체 | 고순도의 금속막 제조방법 |
US20040038303A1 (en) * | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
US20050136033A9 (en) * | 2002-08-13 | 2005-06-23 | Matthias Mack | Method of treating allergen induced airway disease |
US20060257359A1 (en) * | 2005-02-28 | 2006-11-16 | Cedric Francois | Modifying macrophage phenotype for treatment of disease |
EP1698902A1 (en) * | 2005-03-01 | 2006-09-06 | DKFZ Deutsches Krebsforschungszentrum | Use of XCR1 for diagnosing or monitoring of immune tolerance |
-
2007
- 2007-11-20 EP EP07022471A patent/EP2062592A1/en not_active Withdrawn
-
2008
- 2008-11-19 BR BRPI0819295 patent/BRPI0819295A2/pt not_active Application Discontinuation
- 2008-11-19 CN CN200880117058.7A patent/CN101896191B/zh active Active
- 2008-11-19 JP JP2010534403A patent/JP2011503219A/ja active Pending
- 2008-11-19 US US12/741,798 patent/US10703817B2/en active Active
- 2008-11-19 WO PCT/EP2008/009758 patent/WO2009065561A2/en active Application Filing
- 2008-11-19 CA CA2705588A patent/CA2705588A1/en not_active Abandoned
- 2008-11-19 AU AU2008328183A patent/AU2008328183B2/en active Active
- 2008-11-19 MX MX2010005451A patent/MX2010005451A/es active IP Right Grant
- 2008-11-19 EP EP08852540.7A patent/EP2200633B1/en active Active
-
2014
- 2014-07-23 JP JP2014150090A patent/JP5946494B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US20100310562A1 (en) | 2010-12-09 |
CA2705588A1 (en) | 2009-05-28 |
JP5946494B2 (ja) | 2016-07-06 |
AU2008328183B2 (en) | 2013-12-12 |
AU2008328183A1 (en) | 2009-05-28 |
CN101896191B (zh) | 2017-08-25 |
WO2009065561A8 (en) | 2010-06-10 |
EP2200633A2 (en) | 2010-06-30 |
WO2009065561A3 (en) | 2009-09-03 |
WO2009065561A2 (en) | 2009-05-28 |
JP2015007052A (ja) | 2015-01-15 |
BRPI0819295A2 (pt) | 2015-05-05 |
JP2011503219A (ja) | 2011-01-27 |
EP2062592A1 (en) | 2009-05-27 |
CN101896191A (zh) | 2010-11-24 |
US10703817B2 (en) | 2020-07-07 |
EP2200633B1 (en) | 2018-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010005451A (es) | Sistema para la liberacion en una celula positiva para xcr1 y usos de este. | |
NZ703820A (en) | Permeant delivery system and methods for use thereof | |
MX2014007233A (es) | Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados. | |
IN2015DN00255A (es) | ||
WO2006084131A3 (en) | Furin inhibitors and alpha-defensins for the treatment or prevention of papillomavirus infection | |
MX354840B (es) | Nanocapsulas que contienen microemulsiones. | |
WO2010036918A3 (en) | Intracellular dna receptor | |
MX350082B (es) | Moleculas de entrega selectiva y metodos de uso. | |
MX343360B (es) | Conjugados peptidicos de agonistas del receptor de glp-1 y gastrina y su uso. | |
CL2009000393A1 (es) | Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular. | |
AU2009326524A8 (en) | Use of Flt3 ligand for strengthening immune responses in RNA immunization | |
WO2008036929A3 (en) | Complex for transferring an anionic substance into a cell | |
MX2018006299A (es) | Analogos de peptido de la hormona de estimulacion de alfa-melanocito. | |
HK1140940A1 (en) | Titration of tapentadol | |
NZ612285A (en) | Enhanced immune response in bovine species | |
MX2010005385A (es) | Medicamentos topicos para la terapia antimicotica. | |
EP2591792A4 (en) | NUCLEIC ACID ADMINISTRATION COMPOSITION, EXCIPIENT COMPOSITION, PHARMACEUTICAL COMPOSITION CONTAINING NUCLEIC ACID ADMINISTRATION COMPOSITION OR EXCIPIENT COMPOSITION, AND NUCLEIC ACID DELIVERY METHOD | |
WO2008063842A3 (en) | Methods of treating neuropathic pain with agonists of ppar-gamma | |
EP2232430A4 (en) | METHOD OF MANAGING MEDICAL PRODUCTS | |
EP2548022A4 (en) | MULTI-PHASE MICROARRAYS AND USES THEREOF | |
MY161268A (en) | PEPTIDE OR PEPTIDE COMPLEX BINDING TO α2 INTEGRIN AND METHODS AND USES INVOLVING THE SAME | |
MX2010010457A (es) | Vectores recombinantes de rinovirus. | |
MX2011004483A (es) | Leucolectinas y sus usos. | |
EP2552462A4 (en) | CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE | |
NZ590469A (en) | Treatment of rheumatoid arthritis with human beta defensins (1-4) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |